Assessment of HIV‐1 screening test sensitivities using serially diluted positive sera can give misleading results
- 1 January 1989
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 29 (1) , 78-80
- https://doi.org/10.1046/j.1537-2995.1989.29189101171.x
Abstract
Three FDA licensed HIV‐1 viral lysate and two nonlicensed recombinant antigen assays were used to evaluate six serially diluted plasma samples and 2 highly characterized seroconversion series. The sensitivity as measured by serial dilution did not necessarily correlate with the sensitivity as measured by seroconversion performance with the lysate and the recombinant assays. It is concluded that national licensing agencies should arrange to share seroconversion panels to evaluate accurately the sensitivity of new HIV‐1 screening tests.This publication has 5 references indexed in Scilit:
- Evaluation of Three Second‐Generation and Three Confirmatory Assays for Antibodies to Human Immunodeficiency VirusVox Sanguinis, 1988
- Summary of the Centers for Disease Control Human Immunodeficiency Virus (HIV) Performance: Evaluation Surveys for 1985 and 1986American Journal of Clinical Pathology, 1988
- Comparison of two commercially available anti‐HIV ELISAs: Abbott HTLV III EIA and Du Pont HTLV III‐ELISAJournal of Medical Virology, 1987
- Enzyme immunoassay using a novel recombinant polypeptide to detect human immunodeficiency virus env antibodyJournal of Clinical Microbiology, 1987
- Studies of the sensitivity and reproducibility of commercial kits to detect antibodies to the human immunodeficiency virusTransfusion, 1987